1. Enrique Quintero, Antoni Castells,Luis Bujanda, Joaquín Cubiell, Dolores Salas,Ángel Lanas, et COLONPEV study. Colonoscopy versus Fecal Immunochemical Testing in Colorectal-CancerScreening. February 23, 2012N Engl J Med 2012; 366:697-706 DOI: 10.1056/NEJMoa1108895

2. Juan Diego Morillas, Antoni Castells, Isabel Oriol, Ana Pastor, Pedro Pérez-Segura, José Manuel Echevarría et al. Alianza para la Prevención del Cáncer de Colon en España: un compromiso cívico con la sociedad. Gastroenterol Hepatol 2012; 35:109-28 - DOI: 10.1016 /j.gastrohep.2012.01.002.

3. Portillo I, Idigoras I, Ojembarrena E, Arana E, Zubero MB, Pijoán JI et al. Principales resultados del programa de cribado de cáncer colorrectal en el País Vasco. Gac Sanit. 2013; 27; 4: 358–361.

4. Portillo I, Idigoras I, Ojembarrena E, Arana E et al. Lesiones detectadas en el programa de cribado de cáncer colorrectal en el País Vasco: primera ronda 2009-2011. Gastroenterol Hepatol. 2013; 36; 5: 301-308. DOI.org/10.1016/j.gastrohep.2013.02.004.

5. Jover R, Zapater P, Polanía E, Bujanda L, Lanas A, Hermo JA and COLONPREV study. Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. Clinical Endoscopy 2013; 77: 381-9. DOI: org/10.1016/j.gie.2012.09.027

6. Hernández V, Cubiella J, González-Mao C, Rivera C, Iglesias MB, Cid L et COLONPREV study. Fecal immunochemical test accuracy in average-risk colorectal cancer screening. World J Gastroenterol. 2014; 20; 4:1038-47. doi: 10.3748/wjg.v20.i4.1038.

7. Zubero MB, Arana-Arri E, Pijoán JI, Portillo I, Idigoras I, López-Urrutia A. et al. Population-based colorectal cancer screening: comparison of two fecal occult blood test. Frontiers in Pharmacology 2014; 4; 175: 1-8. DOI: 10.3389/fphar.2013.00175.

8. Antoni Castells, Enrique Quintero, Cristina Álvarez,Luis Bujanda, Joaquín Cubiella, Dolores Salas et al. Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests. Clinical Gastroenterology and Hepatology 2014;12:1708–1716. DOI.org/10.1016/j.cgh.2014.03.022

9. Cubiella J, Castro I, Hernandez V, González-Mao C, Rivera C, Iglesias F et al. Characteristics of Adenomas Detected by Fecal Immunochemical Test in Colorectal Cancer Screening. Cancer Epidemiol Biomarkers Prev 2014 DOI:10.1158/1055-9965.EPI-13-1346.

10. Salas D, Vanaclocha M, Ibañez J, Molina-Barcelo A, Hernández V, Cubiella J et COLONPREV study. Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening. Cancer Causes Control 2014; 8:985-97.DOI: 10.1007/s10552-014-0398-y.

11. Joaquín Cubiella, Inés Castro, Vicent Hernandez, Carmen González-Mao, Concepción Rivera, et al. Diagnostic accuracy of fecal immunochemical test in average- and familial-risk colorectal cancer .United European Gastroenterology Journal published online 24 September 2014; 2; 6: 522–529. DOI: 10.1177/2050640614553285

12. Bujanda L, Sarasqueta C, Lanas Á, Quintero E, Cubiella J, Hernandez V, et COLONPREV study. Effect of oral anticoagulants on the outcome of faecal

immunochemical test. BJC 2014; 4;110;5:1334-7. DOI: 10.1038/bjc.2014.38

13. Bujanda L, Sarasqueta C, Castells A, Pellise M, Cubiella J, Gil I, et al. Colorectal cancer in a second round after a negative faecal immunochemical test. Journal of Gastroenterology. 2015 DOI: 1097/MEG.0000000000000366.

14. Hurtado JL, Bacigalupe A, Calvo M, Esnaola S, Mendizabal N, Portillo I, et al. Social inequalities in a population based colorectal cancer screening programme in the Basque Country. BMC Public Health 2015; 15:1021. DOI: 10.1186/s12889-015-2370-5.

15. Salas D, Portillo I, Espinás JA, Ibañez J, Vanaclocha M, Perez-Riquelme F, de la Vega M and Spanish Cancer Screening Network. Implementation of colorectal cancer screening in Spain: main results 2006-2011. European Journal of Cancer Prevention 2016 DOI: 10.1097/CEJ.0000000000000232.

16. Cristina Alvarez-Urturi, Montserrat Andreu, Cristina Hernandez, Francisco Perez-Riquelme, Fernando Carballo, Akiko Ono et COLONPREV study. Impact of age and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. Digestive and Liver Disease 2016; 48: 542-551. DOI.org/10.1016/j.dld.2016.02.001.

17. Rodrigo Jover, Michael Bretthauer , Evelien Dekker, Øyvind Holme, Michal F. Kaminski, Magnus Løberg et al. The European Polyp Surveillance (EPoS) trials – Rationale, Design and Methodology. Endoscopy 2016; 48; 6: 571–578. DOI:10.1055/s-0042-104116.

18. Joaquín Cubiella, Fernando Carballo, Isabel Portillo, José Cruzado Quevedo, Dolores Salas, Gemma Binefa et al. Incidence of advanced neoplasia during surveillance in high- and intermediate-risk groups of the European colorectal cancer screening guidelines. Endoscopy 2016 DOI http://dx.doi.org/10.1055/s-0042-112571 .

19. Portillo I, Arana-Arri E, Idigoras I, Espinás JA, Pérez-Riquelme F, de la Vega M, González A y grupo CRIBEA. Proyecto CRIBEA: Lesiones detectadas en seis Programas Poblacionales de Cribado de Cáncer Colorrectal en España. Rev Esp Salud Pública 2017; 91; 20 Febrero e1-e10.

20. Portillo I, Arana-Arri E, Idigoras I, Bilbao I, Martínez-Indart L, Bujanda L, et al. Colorectal and interval cancers of the colorrectal cancer screening program in the Basque Country (Spain). World Gastroenterol 2017; 23; 15: 2731-2742.

21. Arana-Arri E, Idigoras I, Uranga B, Pérez R, Irurzun A, Gutiérrez-Ibarluzea I et al. Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex? BMC Cancer. 2017; 17;577:1-13. DOI 10.1186/s12885-017-3555-3.

22. Mercedes Vanaclocha-Espi, Josefa Ibáñeza, Ana Molina-Barceló, Elena Pérez, Andreu Nolasco, Rebeca Font and CRIBEA group. Factors influencing participation in colorectal cancer screening programs in Spain.Preventive Medicine 2017; 105: 190–196. doi.org/10.1016/j.ypmed.2017.08.019.

23. Idigoras I, Arrospide A, Portillo I, Arana-Arri E, Martínez-Indart L, Mar J, et al. Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-Colon model. BMC Public Health. 2017. DOI 10.1186/s12889-017-4639-3.

24. Arana-Arri E, Imaz-Ayo N, Fernandez-Landa MJ, Idigoras I, Bilbao I, Bujanda L et al. Screening colonoscopy and risk of adverse events among individuals undergoing fecal immunochemical testing in a population-based program: A nested case-control study. United European Gastroenterology Journal 2018; 6; 5: 755–764. DOI: 10.1177/2050640618756105.

25. Arrospide A , Idigoras I, Mar J, de Koning H, van der Meulen M, Soto-Gordoa M et al.Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model. BMC Cancer 2018; 18: 464. https://doi.org/10.1186/s12885-018-4362-1 .

26. López de Argumedo M, Reviriego E, Portillo I. Prueba inmunológica de sangre oculta en heces en pacientes con sintomatología compatible con cáncer colorrectal: Recomendaciones de las Guías de Práctica Clínica y su utilización en el Sistema Nacional de Salud. Ministerio de Sanidad, Servicios Sociales e Igualdad. Servicio de Evaluación de Tecnologías Sanitarias del País Vasco; 2018. Informes de Evaluación de Tecnologías Sanitarias: OSTEBA. http://www.bibliotekak.euskadi.eus/webOpac

27. Portillo I, Idigoras I, Bilbao I, Arana-Arri E, Fernández-Landa MJ, Hurtado JL and EUSKOLON Study Investigators. Colorectal cancer screening program using FIT: quality of colonoscopy varies according to hospital type. Endoscopy International Open 2018; 06: E1149–E1156. DOI https://doi.org/10.1055/a-0655-1987.

28. Portillo I, Arana-Arri E, Gutierrez-Ibarluzea I, Bilbao I, Hurtado JL, Sarasqueta C and EUSKOLON Study Investigators. Factors related to the participation and detection of lesions in colorectal cancer screening programme-based faecal immunochemical test. European Journal of Public Health 2018; 1–6. doi:10.1093/eurpub/cky109.

29. Iago Rodríguez-Lago, Olga Merino, Irene Azagra, Ainara Maiz, Eva Zapata, Rebeca Higuera et al. Characteristics and Progression of Preclinical Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2018;16:1459–1466. DOI.org/10.1016/j.cgh.2017.11.006.

30. Isabel Portillo, Isabel Idigoras, Isabel Bilbao, Eunate Arana-Arri, Luis Bujanda eta EUSKOLON taldea. Koloneko eta ondesteko minbizia bahetzeko programaren 10. urtea Euskadin. Osagaiz – 2018 – 2. bolumena – 2. zk. – 35. DOI.org/10.26876/osagaiz.2.2018.174.

31. Fernández-Landa MJ, Aginagalde AH, Arana-Arri E, Bujanda L, Idígoras I, Bilbao I et al. Indicadores de calidad y satisfacción de los pacientes en la colonoscopia. Gastroenterología y Hepatología 2019; 42; 2:73-81 DOI.org/10.1016/j.gastrohep.2018.07.006.

32. Vanaclocha-Espi M, Ibáñez J, Molina-Barceló A, Valverde-Roig MJ, Pérez E, Nolasco A and CRIBEA group. Risk factors for severe complications of colonoscopy in screening programs Preventive Medicine 2019; 118: 304–308. DOI.org/10.1016/j.ypmed.2018.11.010.

33. Isabel Idigoras, Eunate Arana-Arri, Isabel Portillo, Isabel Bilbao, Lorea Martínez-Indart, Natale Imaz-Ayo et al. Participation in a population-based screening for colorectal cancer using the faecal immunochemical test decreases mortality in 5 years. European Journal of Gastroenterology & Hepatology 2019; 31; 2: 197-204. DOI: 10.1097/MEG.0000000000001338.

34. Esther Toes-Zoutendijk, Isabel Portillo, Sarah Hoeck, Isabel de Brabander, Philippe Perrin, Catherine Dubois et al. Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe. J Med Screen 2019 DOI: 10.1177/0969141319879712.

35. Iker Alegria-Lertxundi, Carmelo Aguirre, Luis Bujanda, Francisco Javier Fernandez, Francisco Polo, Jose M. Ordovas et al. Single nucleotide polymorphisms associated with susceptibility for development of colorectal cancer: Case-control study in a Basque population. PLOS ONE 2019. DOI.org/10.1371/journal.pone.0225779.

36. Noel Pin-Vieito, Laura García Nimo, Luis Bujanda, Begoña Román Alonso, María Angeles Gutierrez-Stampa,Vanessa Aguilar-Gama, Isabel Portillo and Joaquín Cubiella. Optimal diagnostic accuracy of quantitative faecal immunochemical test positivity thresholds for colorectal cancer detection in primary health care: A community-based cohort study. United European Gastroenterology Journal 0(0) 1–11 2020.
DOI: 10.1177/2050640620949714.

37. Unanue-Arza S, Arana-Arri E, Portillo I,Arostegui I. Implicación de los profesionales de atención primaria en el programa de detección precoz de cáncer colorrectal del País Vasco. Rev Esp Salud Pública. 2021; 95: 26 de enero e202101012.

38. Fernández Landa MJ, Portillo Villares MI, Bilbao Iturribarria MI, Idígoras Rubio MI, Regulez Campo V, Martínez Indart L. Impacto de una intervención en las consultas de Enfermería de Atención Primaria para la mejora de la calidad de la colonoscopia de cribado. Metas Enferm mar 2020; 23(2):16-22. https://doi.org/10.35667/MetasEnf.2019.23.1003081547.

39. Saloa Unanue-Arza, Maite Solís-Ibinagagoitia, Marta Díaz-Seoane, Isabel Mosquera-Metcalfe, Isabel Idigoras, Isabel Bilbao, Isabel Portillo. Inequalities and risk factors related to non- participation in colorectal cancer screening programmes: a systematic review. European Journal of Public Health, ckaa203, December 2020. https://doi.org/10.1093/eurpub/ckaa203

40. Solís-Ibinagagoitia M, Unanue-Arza S,Díaz-Seoane M, Martínez-Indart L, Lebeña-Maluf A, Idigoras I, Bilbao I and Portillo I (2020) Factors Related to Non-participation in the Basque Country Colorectal Cancer Screening Programme. Front. Public Health 8:604385.
Doi: 10.3389/fpubh.2020.604385.

41. María Angeles Gutierrez-Stampa, Vanessa Aguilar, Cristina Sarasqueta, Joaquín Cubiella, Isabel Portillo and Luis Bujanda. Impact of the faecal immunochemical test on colorectal cancer survival. BMC Cancer (2020) 20:616. https://doi.org/10.1186/s12885-020-07074-y

42. Isabel Mosquera, Nere Mendizabal, Unai Martín, Amaia Bacigalupe, Elena Aldasoro,Isabel Portillo; from the Desberdinak Group. Inequalities in participation in colorectal cáncer screening programmes: a systematic review. European Journal of Public Health, Volume 30, Issue 3, June 2020, Pages 558–567. https://doi.org/10.1093/eurpub/ckz236.

43. Carolina Mangas-Sanjuan, Enrique Santana, Joaquín Cubiella, Elena Rodríguez-Camacho, Agustín Seoane, Marco Antonio Alvarez-Gonzalez et al. Variation in Colonoscopy Performance Measures According to Procedure Indication. Clinical Gastroenterology and Hepatology 2020;18:1216–1223. https://doi.org/10.1016/j.cgh.2019.08.035